This website uses cookies to make your browsing experience more efficient and enjoyable. You can find out more about which cookies we are using or switch them off in settings. Allow cookies
Cookies are small, simple text files which your computer, tablet or mobile phone receives when you visit a website. There are various kinds of cookies: from basic to advanced that makes the website more personal and advanced cookies make it easier to use a website. Choose your own level of cookies. The higher the level, the easier you will find the website to use.
Learn more about cookies
More information on our privacy policy
...we are obliged to ask your permission before placing any cookies on your computer. This website uses cookies to make your browsing experience more efficient and enjoyable.
Get the latest from WNS in your mailbox
With the high cost of bringing a new drug to market, pharmaceutical companies need to zero in quickly on which drugs show the best potential for medical results and growth. Therefore, companies are increasingly making the effort to identify these drugs earlier in the development process, by better understanding and targeting patient populations. This requires aggregating and analyzing data from a number of internal and external medical, economic, and social sources.
WNS has positioned itself for research and analytics expertise to support drug development and commercial services activities with a scope of services to understand and address a targeted patient population by therapeutic and geographic area, and the competitive positioning of the pharma company. Its recent acquisition of Value Edge Services brings in complementary leadership, talent, and tools.
In our recent HfS Blueprint on Pharma BPO for R&D and Commercial Services, we noted that while WNS has a proven model for integrating with client research and analytics teams at pharmaceutical companies, it is in early stages of developing tools and a broader talent base.
To read this blog further, please visit http://www.hfsresearch.com/pointsofview/wns-acquires-pharma-research-talent-and-tools